Make A Donation

The Food and Drug Administration on Wednesday approved Botox injections to treat urinary incontinence in patients with neurological conditions like spinal cord surgery or multiple sclerosis, opening the door to even broader uses of the popular nerve-blocking agent.

It was the seventh medical condition the F.D.A. has approved for Botox since its introduction in 2002 as a cosmetic wrinkle remover, Allergan said in a statement.

The drug has been studied for more than 100 medical conditions in all, according to Caroline Van Hove, company spokeswoman. “Anything from writer’s cramp to anal fissure to Parkinson’s disease. That’s why we say it’s a pipeline in a vial,” she said Wednesday.

Botox sales last year were about $1.5 billion worldwide, roughly half cosmetic and half therapeutic. Allergan, of Irving, Calif., predicts sales will grow more in the therapeutic arena.

The next study in a late-stage trial is using Botox to treat urinary incontinence for unknown causes, a much larger market than the estimated 340,000 people in the United States with incontinence from nerve conditions, Ms. Van Hove said. One injection in the bladder can help control incontinence for about nine months, the F.D.A. said in a news release.